


Serial No. 09/971,799  
Attorney Docket No. PG4113US2

### REMARKS/ ARGUMENTS

This Supplemental Amendment is submitted in response to the final Office Action mailed October 29, 2003 (the Action) and the Advisory Action mailed January 23, 2004. Currently Claims 1-55, 57-71, 81-105, 109-113, and 116-125 are pending. Applicants appreciate the indication that Claims 1-24, 26-55, 57-71, 81-104, and 125 are allowed. Applicants have canceled Claims 25, 105, 109-113 and 116-124, without prejudice to pursuing the subject matter of these claims in a continuing application.

Applicants respectfully request that this Supplemental Amendment be entered and that a Notice of Allowance be issued forthwith. Applicants encourage the Examiner to direct any questions to the undersigned, who may be contacted at (919) 483-9024.

Respectfully submitted:

  
J. Michael Strickland  
Attorney for Applicants  
Reg. No. 47,115

Date: February 26, 2004  
GlaxoSmithKline Inc.  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709  
Tel. (919) 483-9024  
Fax: (919) 483-7988